Reference

Studies on

Studies on .gamma.-oryzanol. II. The antiulcerogenic action. Itaya, Kimikazu; Kiyonaga, Jiosuke; Ishikawa, Muneyoshi (Res. Inst., Otsuka Pharm. Co., Ltd., Tokushima, Japan). Nippon Yakurigaku Zasshi, 72(8), 1001-11 (Japanese) 1976. CODEN: NYKZAU. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) In rats, the circadian rhythm of stress ulceration showed a peak at 2:00 p.m. The antiulcerogenic action of .gamma.-oryzanol (I) [11042-64-1] (100 mg/kg/day, s.c., for 5 days) pretreatment was significant when rats were stressed for 6 h starting at 2:00 a.m., 5:00 a.m., a.m., or 2:00 p.m. An 8-day treatment with I had antiulcerogenic action against ulcers induced by fasting, while 5-day treatment had only slight effects on ulcers in Shay rats and on ulcers induced by stress plus atropine. No correlation was obsd. between the antiulcerogenic effect of I and serum gastrin levels. Pretreatment with reserpine, .alpha.-methyltyrosine, and DL-p-chlorophenylalanine before stress loading suppressed the antiulcerogenic action of I. The suppression by reserpine was slightly inhibited by L-deoxyphenylalanine. Thus, the monoaminergic nervous system appears to be involved in the antiulcerogenic action of I. The antiulcerogenic activity of I was compared to that of atropine and sulpiride.

Effect of g-oryzanol and its related compounds on triton-induced hyperlipidemia in rats

Effect of g-oryzanol and its related compounds on triton-induced hyperlipidemia in rats. Nakayama, Sadao; Kurishima, Hideyuki; Kobayashi, Kenji; Tasuji, Taiki (Sch. Med., Showa Univ., Tokyo 142, Japan). Showa Igakkai Zasshi, 46(3), 359-64 (Japanese) 1986. CODEN: SIGZAL. ISSN: 0371-0254. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) In rats with hyperlipidemia induced by triton WR 1339 , the excretion of free cholesterol [57-88-5] and triglyceride was accelerated by i.Several substances with their cas registry numbers 21238-33-5 and 57-88-5 may be metioned in this study.v. injection of g-oryzanol [11042-64-1] and its related compds., new g-oryzanol (with different compn. in sterol ratio) and cycloartenol ferulic acid ester [21238-33-5]; this antihyperlipidemic effect of g-oryzanol was weaker than its related compds., and the synthesis of lipoproteins was not inhibited by g-oryzanol or its related compds. .